Meibomian gland dysfunction
Conditions
Interventions
Treatment group:Allergic conjunctivitis conventional drug treatment +IPL treatment
Sponsors
Wenzhou Medical University Affiliated Eye Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 88 Years
Inclusion criteria
Inclusion criteria: 1. To be diagnosed with meibomian gland dysfunction (MGD), any one of the following criteria must be met (based on the "Expert Consensus on Meibomian Gland Dysfunction in China (2023)") : abnormal meibomian gland opening (opening blockage, stenosis, displacement, atresia or congenital absence), abnormal meibomian gland discharge capacity and/or abnormal secretion properties. 2. Subjects over 8 years old who have been diagnosed with active moderate or severe spring keratoconjunctivitis should visit the outpatient department and cooperate with the MGD examination. 3. Parents agree to have their children undergo clinical tests and comprehensive ocular surface analysis tests. 4. A history of spring keratoconjunctivitis for more than one year, including children who have already used VKC drugs and those who have admitted and recorded the drugs.
Exclusion criteria
Exclusion criteria: 1. History of ocular trauma: Subjects with a history of ocular trauma were excluded. 2. Active ocular infection: Exclude any subjects with active ocular infection that may potentially confuse the research results. 3. In the past three months, local or systemic drugs that affect meibomian gland function, such as azithromycin, doxycycline, and isotretinoin, have been used. 4. Subjects with definite infectious blepharitis (such as bacterial, fungal or parasitic infections) were excluded. 5. Subjects with active corneal ulcers or unhealed corneal epithelial defects were excluded 6. Subjects who simultaneously suffer from diseases that may be triggered by light with wavelengths ranging from 500nm to 1200nm, such as simple recurrent herpes, systemic lupus erythematosus, and porphyria. 7. Pregnant and lactating subjects. 8. Subjects who have received radiotherapy or chemotherapy within the last year, or those who plan to undergo radiotherapy or chemotherapy within two months after IPL treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Conjunctival Hyperemia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Eyelid margin morphology;Corneal fluorescein staining;Tear film rupture;Conjunctival papillae;The eyelid margin is congested;Conjunctival follicle;Meibomian gland secretion;Horner-Trantas nodules; | — |
Countries
China
Contacts
Public ContactChen Wei
Wenzhou Medical University Affiliated Eye Hospital
Outcome results
None listed